52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
Aug 23 (Reuters) - NantKwest Inc <NK.O>::NANTKWEST INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING.
March 25 (Reuters) - NantKwest Inc <NK.O>::NANTKWEST CHAIRMAN & CEO DR. PATRICK SOON-SHIONG EXERCISES $39 MILLION IN WARRANTS AND OPTIONS IN SUPPORT OF NK’S NATURAL KILLER CELL STRATEGIC VISION BEYOND CHECK POINT IMMUNOTHERAPY.NANTKWEST INC - FUNDING TO SUPPORT INDS FOR FIRST-IN-HUMAN TARGETED OFF--SHELF NK CELLS (T-HANKS) WITH PD-L1 AND CD-19 AS TUMOR TARGETS.NANTKWEST INC - CHAIRMAN & CEO EXERCISED WARRANTS WITH AN EXERCISE PRICE OF $1.9984 AND OPTIONS WITH AN EXERCISE PRICE OF $2.1983.
June 19 (Reuters) - NantKwest Inc <NK.O>::NANTKWEST NAMES SONJA NELSON CHIEF FINANCIAL OFFICER.NELSON SUCCEEDS RICH TAJAK, WHO HAD SERVED AS COMPANY'S CFO SINCE JANUARY 2016.
June 13 (Reuters) - NantKwest Inc <NK.O>::NANTKWEST INC - EFFECTIVE AS OF JUNE 11, 2018, APPOINTED SONJA NELSON AS CHIEF FINANCIAL OFFICER.NANTKWEST SAYS EFFECTIVE AS OF JUNE 11, 2018, RICHARD TAJAK HAS STEPPED DOWN AS CFO- SEC FILING.
July 25 (Reuters) - Nantkwest Inc <NK.O>::Nantkwest announces publication of preclinical data of hank cell therapy in combination with checkpoint inhibitor avelumab providing strong rationale for advancement to human clinical trials.
June 6 (Reuters) - Nantkwest Inc <NK.O>::NantKwest expands nant cancer vaccine program with additional clinical trials announced addressing multiple cancer types across all stages of disease.NantKwest Inc - expansion of company's existing nant cancer vaccine program in pancreatic cancer to target a number of additional tumor types.NantKwest - first combination off shelf NK, adaptive immunotherapy trial to be initiated for pancreatic, lung, breast and colon cancer, among others.
May 9 (Reuters) - Nantkwest Inc <NK.O>:Nantkwest and nantcell announce fda authorization for the nant cancer vaccine clinical trials, the first novel combination of innate and adaptive immunotherapy in patients with pancreatic cancer.
NantKwest Inc <NK.O>: NantKwest and Viracta Therapeutics announce series b financing and immunotherapy partnership .NantKwest - co, Viracta Therapeutics announced initial closing of a series b preferred financing round of up to $18.4 million with co as lead investor.
Nantkwest Inc <NK.O>:Nantkwest announces FDA grant of orphan drug designation for the company's ank natural killer cell therapy in merkel cell carcinoma.
NantKwest Inc <NK.O> - :NantKwest - U.S. FDA has authorized co's IND for its first-in-human, high-affinity natural killer (haNK) cell therapy Phase I clinical study.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.